NeOnc Technologies Holdings is trading at $3.32 (6.2% down) today as investors weigh ongoing dilution risks and the company’s cash needs following recent financing and share sale activity against positive regulatory developments. - The stock continued a multi-day selloff on July 15, after receiving generally positive written FDA feedback on NEO212's manufacturing and controls development program. - The FDA deemed NeOnc's proposed approach "reasonable", but traders appear to prioritize long-term capital requirements over clinical progress.